Investor Presentaiton
Strengthen Portfolio
Best, early-stage translational portfolio from one integrated partner
Enhancing our scientific capabilities with a focus on advanced modalities (incl.
C>) and key therapeutic areas
Continue to expand expertise around humanized models, CRADL™, antibody discovery,
bioanalysis and advanced screening capabilities, microbial detection, process
development, and next-generation sequencing
■ Selectively adding to portfolio via technology partnerships and our M&A
roadmap to create even more compelling value for our clients
Will also evaluate creative and new opportunities to partner with emerging biotech clients
earlier in the R&D process, including our VC relationships and biohubs strategy
Enable clients to advance their drugs to the clinic and commercial phase faster
and more efficiently
Charles River Laboratories (CRL)
18View entire presentation